Pharma Two B rakes in $30 mln
Israel-based Pharma Two B Ltd, a biopharmaceutical company focused on developing treatments for Parkinson's disease, has secured $30 million in funding. Israel Biotech Fund led the round with participation from other investors that included JK&B and Generali Financial Holdings FCP-FIS SF2. In conjunction with the funding, Jeff Kindler, a member of Israel Biotech Fund's venture advisory team, has been added to Pharma Two B's board of directors.
27 February 2017•1 min read
